1,000 Physicians, 4,500 Patients Enrolled In Tysabri TOUCH Program
This article was originally published in The Pink Sheet Daily
Executive Summary
Elan reports early data on uptake of the MS therapy, but says it is too early to tell how many enrollees will convert to patients treated.
You may also be interested in...
Biogen Idec Sales Of Avonex Dip In U.S. As Tysabri Gains Ground
Review of acquisition bids for the firm could take “a number of months,” CEO Mullen reports.
Biogen Idec Sales Of Avonex Dip In U.S. As Tysabri Gains Ground
Review of acquisition bids for the firm could take “a number of months,” CEO Mullen reports.
Biogen Idec Shifts Gears On Tysabri Relaunch
“Phase II” will focus on efficacy and broadening use of the multiple sclerosis therapy, CEO Mullen tells investors.